Velpatasvir

Drug Profile

Velpatasvir

Alternative Names: GS-5816

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Pyrrolidines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(Treatment-naive) in Puerto Rico (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(Treatment-naive) in USA (PO, Tablet)
  • 26 Jan 2015 Gilead Sciences and Mylan Laboratories agree to distribute velpatasvir worldwide for Hepatitis C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top